The subject of present invention is to provide a medicament related to incretin hormone for completely inhibiting secretion of GIP and simultaneously promoting secretion of GLP-1, and with excellent safety. The solution of present invention is to provide a medicament for promoting secretion of GLP-1 (glucagons-like peptide-1) and inhibiting secretion of GIP (glucose-dependent insulin secretion stimulation polypeptide), which is characterized in that comprises sucrose decomposition enzyme being a non-antagonistic type inhibitor, such as L-arabinose, D-xylose and D-tagatose, as the active ingredient.
